Mesenchymal Stem Cell Derived Exosomes: A New Hope for the Treatment of Cardiovascular Disease?

Cardiovascular disease is a major target for numerous experimental stem (progenitor) cell-based therapies. Mesenchymal stem cells (MSCs) from different sources confer regenerative effects in animal models of cardiovascular disease. Some of these investigations have proceeded into phase I and II clinical trials for limb ischemia, heart failure, and acute myocardial infarction. The rationale for MSC therapy is increasingly recognized on a secretion (paracrine) rather than differentiation mechanism. Recently, several groups have demonstrated that the ＂exosome＂ is a secreted agent mediating MSC therapeutic efficacy. Unlike cell therapy, exosomes have no risk of aneuploidy, and a lower rate of immune rejection following allogeneic administration. In this short review, we will focus on the potential of using this novel therapeutic modality for the treatment of cardiovascular disease, particularly acute myocardial infarction.

[1]  R. B. Richardson,et al.  A Systematic Review of Preclinical Studies on the Therapeutic Potential of Mesenchymal Stromal Cell-Derived Microvesicles , 2015, Stem Cell Reviews and Reports.

[2]  R. Liao,et al.  Regenerative therapy for cardiovascular disease. , 2014, Translational research : the journal of laboratory and clinical medicine.

[3]  B. Yu,et al.  Exosomes Derived from Mesenchymal Stem Cells , 2014, International journal of molecular sciences.

[4]  Gerard Pasterkamp,et al.  Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. , 2013, Stem cell research.

[5]  Seok-Goo Cho,et al.  The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation , 2013, Experimental & Molecular Medicine.

[6]  Joshua M Hare,et al.  Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.

[7]  M. Simões,et al.  Bone Marrow-Derived Mesenchymal Stem Cells Repaired but Did Not Prevent Gentamicin-Induced Acute Kidney Injury through Paracrine Effects in Rats , 2012, PloS one.

[8]  Patrick W Serruys,et al.  First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. , 2012, Journal of the American College of Cardiology.

[9]  M. Monajemzadeh,et al.  Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient with dilated cardiomyopathy , 2011, Pediatric transplantation.

[10]  S. Cheong,et al.  Intramyocardial and intracoronary autologous bone marrow-derived mesenchymal stromal cell treatment in chronic severe dilated cardiomyopathy. , 2011, Cytotherapy.

[11]  S. Lim,et al.  Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. , 2011, Regenerative medicine.

[12]  B. Hesse,et al.  Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina , 2011, Scandinavian cardiovascular journal : SCJ.

[13]  M. Goumans,et al.  Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. , 2011, Stem cell research.

[14]  Guido Jenster,et al.  Exosomes as biomarker treasure chests for prostate cancer. , 2011, European urology.

[15]  Zhijian Yang,et al.  A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery. , 2010, Cardiovascular therapeutics.

[16]  G. Pasterkamp,et al.  Derivation and characterization of human fetal MSCs: an alternative cell source for large-scale production of cardioprotective microparticles. , 2010, Journal of molecular and cellular cardiology.

[17]  Gerard Pasterkamp,et al.  Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. , 2010, Stem cell research.

[18]  H. Drexler,et al.  Cell therapy for the treatment of coronary heart disease: a critical appraisal , 2010, Nature Reviews Cardiology.

[19]  Joshua M Hare,et al.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. , 2009, Journal of the American College of Cardiology.

[20]  C. Théry,et al.  Membrane vesicles as conveyors of immune responses , 2009, Nature Reviews Immunology.

[21]  Johan Skog,et al.  Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers , 2008, Nature Cell Biology.

[22]  P. Doevendans,et al.  Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. , 2008, Stem cell research.

[23]  D. Prockop,et al.  Concise Review: Mesenchymal Stem/Multipotent Stromal Cells: The State of Transdifferentiation and Modes of Tissue Repair—Current Views , 2007, Stem cells.

[24]  D. Katritsis,et al.  Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[25]  Jun-Jie Zhang,et al.  Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. , 2006, The Journal of invasive cardiology.

[26]  J. Ingwall,et al.  Evidence supporting paracrine hypothesis for Akt‐modified mesenchymal stem cell‐mediated cardiac protection and functional improvement , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  M. Pittenger,et al.  Mesenchymal stem cells and their potential as cardiac therapeutics. , 2004, Circulation research.

[28]  Fei Ye,et al.  Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. , 2004, The American journal of cardiology.

[29]  M. Burnett,et al.  Marrow-Derived Stromal Cells Express Genes Encoding a Broad Spectrum of Arteriogenic Cytokines and Promote In Vitro and In Vivo Arteriogenesis Through Paracrine Mechanisms , 2004, Circulation research.

[30]  Yong-Fu Xiao,et al.  Significant improvement of heart function by cotransplantation of human mesenchymal stem cells and fetal cardiomyocytes in postinfarcted pigs. , 2002, The Annals of thoracic surgery.

[31]  A I Caplan,et al.  Cytokine expression by human marrow‐derived mesenchymal progenitor cells in vitro: Effects of dexamethasone and IL‐1α , 1996, Journal of cellular physiology.

[32]  P. Stahl,et al.  Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes , 1983, The Journal of cell biology.

[33]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[34]  D. Katritsis,et al.  CORONARY ARTERY DISEASE Original Studies Transcoronary Transplantation of Autologous Mesenchymal Stem Cells and Endothelial Progenitors Into Infarcted Human Myocardium , 2005 .